@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_head { this: np:hasAssertion dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_assertion; np:hasProvenance dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_provenance; np:hasPublicationInfo dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_publicationInfo; a np:Nanopublication . dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_assertion a np:Assertion . dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_provenance a np:Provenance . dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_publicationInfo a np:PublicationInfo . } dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_assertion { miriam-gene:7422 a ncit:C16612 . lld:C0007137 a ncit:C7057 . dgn-gda:DGN20684b259a0ebbd694de7fee408bc413 sio:SIO_000628 miriam-gene:7422, lld:C0007137; a sio:SIO_001121 . } dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_provenance { dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_assertion dcterms:description "[Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:24206575; prov:wasDerivedFrom dgn-void:befree-20150227; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20150227 pav:importedOn "2015-02-27"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP770023.RACwsoXsrFhHqv5JKAch7tyYBYpDOG9INQGhoMkQsryHs130_publicationInfo { this: dcterms:created "2015-08-25T14:45:25+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v3.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v3.0.0" . }